Abstract | BACKGROUND AND OBJECTIVE: METHODS: Single-centre, randomized, double-blind, vehicle controlled study in 40 patients with asteatotic eczema. Efficacy was assessed by eczema area and severity index (EASI), investigators global assessment ( IGA), patient's self-assessment, and pruritus severity. RESULTS: After 4 weeks of treatment, EASI, the primary efficacy variable, was reduced by 62+/-7% from baseline in patients on pimecrolimus, compared to 21+/-14% in patients on vehicle (P=0.013). With pimecrolimus there was also a better control of pruritus (P=0.042) at week 4 whereas a better control of disease according to self-assessment could only be observed at weeks 2 (P=0.01) and week 3 (P=0.08). CONCLUSION:
|
Authors | P Schulz, B Bunselmeyer, M Bräutigam, T A Luger |
Journal | Journal of the European Academy of Dermatology and Venereology : JEADV
(J Eur Acad Dermatol Venereol)
Vol. 21
Issue 1
Pg. 90-4
(Jan 2007)
ISSN: 0926-9959 [Print] England |
PMID | 17207174
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dermatologic Agents
- Pharmaceutical Vehicles
- pimecrolimus
- Tacrolimus
|
Topics |
- Adult
- Dermatologic Agents
(administration & dosage, therapeutic use)
- Eczema
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Pharmaceutical Vehicles
- Tacrolimus
(administration & dosage, analogs & derivatives, therapeutic use)
|